Overview
GLSI market data
Price History
GLSI price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GLSI. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Greenwich LifeSciences Receives UK Regulatory Approval To Expand FLAMINGO-01 Phase III Trial With Royal Marsden CollaborationBenzinga · Jul 22, 2026, 10:07 AM
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69Benzinga · Jul 21, 2026, 5:03 PM
Greenwich LifeSciences shares are trading lower after the company provided clinical updates on FLAMINGO-01.Benzinga · Jul 20, 2026, 6:03 PM
Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going ForwardBenzinga · Jul 20, 2026, 10:10 AM
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In EuropeBenzinga · Jul 16, 2026, 11:31 AM
Greenwich LifeSciences shares are trading lower after the company reported worse-than-expected Q4 EPS results.Benzinga · Jun 2, 2026, 3:36 PM
Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) EstimateBenzinga · Jun 1, 2026, 9:50 PM
Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026Benzinga · Jun 1, 2026, 12:19 PM
Greenwich LifeSciences Provides Update Regarding Form 10-K FilingGlobenewswire Inc · Jun 1, 2026, 11:15 AM
Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy TrialBenzinga · Jun 1, 2026, 10:11 AM